Efficacy of S‐1 plus docetaxel in the treatment of metastatic extramammary Paget's disease: a multicentre retrospective study.

In these patients, DOC monotherapy or gemcitabine was the most common treatment approach (two patients), followed by paclitaxel (PTX) monotherapy, PTX/trastuzumab or DOC/trastuzumab. Dear Editor, Metastatic extramammary Paget disease (EMPD) is an intractable condition refractory to conventional treatments; outcomes remain unsatisfactory.1 Establishing an effective regimen with higher response rates and long-term efficacy is needed. Nevertheless, our study revealed that S-1/DOC may be more efficacious than conventional chemotherapy in patients with chemotherapy-naïve metastatic EMPD, with the potential to become a first-line treatment or key regimen in cases of DOC monotherapy failure. [Extracted from the article]
Copyright of British Journal of Dermatology is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)